Compare Quest Diagnostics Inc (DGX) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Enveric Biosciences Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Enveric Biosciences Inc trades at $1.25 (market cap $5.32M). The key difference: Quest Diagnostics Inc is far larger — about 4285.7× Enveric Biosciences Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| DGX | ENVB | |
|---|---|---|
Market Cap | $22.80B | $5.32M |
Sector | Health | Health |
52-Week High | $216.02 | $17.40 |
52-Week Low | $166.42 | $1.28 |
Enterprise Value | $28.82B | $408.82K |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.
While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
